SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

Strona główna・Stock List・Galapagos NV
Search

Galapagos NV

Closed

SectorHealthcare

23.52 -0.84

Sell

Price update 15 maj 2026, 07:43 UTC

BuySell

Overview

Share price change

24h

Current

Min

23.32

Max

23.62

Key metrics

By Trading Economics

Income

-769M

14M

Sales

-894M

6.5M

P/E

Sector Avg

3.182

51.415

EPS

11.9

Profit margin

214.257

Employees

704

EBITDA

-813M

-65M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

+7.35% upside

Dividends

By Dow Jones

Next Earnings

10 sie 2026

Market Stats

By TradingEconomics

Market Cap

-41M

1.6B

Previous open

24.36

Previous close

23.52

News Sentiment

By Acuity

40%

60%

127 / 345 Ranking in Healthcare

Galapagos NV Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

23 mar 2026, 23:47 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Read

23 mar 2026, 22:55 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Read

24 mar 2026, 18:00 UTC

Acquisitions, Mergers, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

Read

24 mar 2026, 14:25 UTC

Acquisitions, Mergers, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

Read

24 mar 2026, 13:35 UTC

Acquisitions, Mergers, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

Read

24 mar 2026, 12:03 UTC

Acquisitions, Mergers, Takeovers

Gilead to Buy Ouro Medicines for $2.2 Billion. 'Immune Reset' Is Key to Future Gains. -- Barrons.com

DJ

Read

23 mar 2026, 22:40 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Read

23 mar 2026, 22:22 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Read

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Read

23 mar 2026, 22:21 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Read

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Read

23 mar 2026, 22:20 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Read

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Read

23 mar 2026, 22:19 UTC

Acquisitions, Mergers, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Read

Peer Comparison

Price change

Galapagos NV Forecast

Price Target

By TipRanks

7.35% upside

12 Months Forecast

Average 25.85 EUR  7.35%

High 30 EUR

Low 22 EUR

Based on 4 Wall Street analysts offering 12 month price targets forGalapagos NV - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

4 ratings

0

Buy

2

Hold

2

Sell

Based on 4 analysts giving stock ratings to Galapagos NV - Dist in the past 3 months.

Sentiment

By Acuity

127 / 345 Ranking in Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Other stocks from the sector

SAN

Sanofi SA

73.96

↑ +1.25%

ARGX

Argenx SE

691.6

↑ +0.03%

SHL.DE

Siemens Healthineers AG

33.51

↓-1.93%

FRE

Fresenius SE & Co KGaA

38.8

↓-0.33%

PHIA

Koninklijke Philips NV

21.75

↓-1.27%
help-icon Live chat